Topic outline
-
In 2021, the European Union (EU) adopted the Health Technology Assessment Regulation (HTAR). This regulation has the aim to harmonise, improve and foster cooperation in Health Technology Assessment (HTA) processes across the EU and between the various relevant Member State HTA bodies.
This regulation introduces a permanent framework for joint work on HTA across the EU and between the Member State HTA authorities that will be applicable from 2025 onwards. The aim is to contribute to improving the availability for EU patients of innovative technologies in health, such as medicines and certain medical devices, to ensure an efficient use of resources and to strengthen the quality of HTA across the Union.
Information on health technology assessment regulation is available from the European Commission's website: EU Health Technology Assessment Regulation.
It remains the remit of the individual MS HTA bodies to assess domains such as economic and social, and to make recommendations and/or decisions on the reimbursement on health technologies at the national level.
Organisation and Key HTA activities of the Regulation
Figure 1: Adapted from Governance and key elements of the HTAR Source: European Commission, 2023. Available at: hta_20230918_co01_en.pdf (europa.eu)
-
View
-
-
-
-
View
-
-
-
View
-
View
-
-
-
Receive a grade Receive a passing grade
-